Dublin, May 11, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects" drug pipelines to their offering.
The increasing demand for type 2 diabetes mellitus (T2DM) therapeutics, caused by rising prevalence of the disease, has resulted in a large and competitive market landscape. There are a number of drugs competing for different market segments, across multiple lines of therapy, according to a business intelligence provider.
The company's latest report states that the emergence over the past decade of glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase 4 inhibitors and sodium-glucose cotransporter 2 inhibitors has intensified competition. These new drug classes have been highly commercially successful and are now well established within the T2DM treatment algorithm.
The leading products within these drug classes are Novo Nordisk's Victoza, Merck's Januvia, and Janssen's Invokana, respectively. In 2015, these drugs generated $2.7 billion, $4.3 billion, and $1.6 billion, respectively.
Fiona Chisholm, Analyst, notes: In spite of recent developments, there are still significant unmet needs for T2DM. Treatment regimens are often complex, and many drugs have limited long-term efficacy and side effects that are particularly undesirable for the T2DM patient population, such as increased cardiovascular risk factors or weight gain.
Alongside the rapidly expanding prevalence population, this ensures that sustained investment in T2DM product innovation continues to be an attractive commercial prospect. Indeed, with 591 products in development, T2DM pipeline activity is very high in comparison to other related indications within metabolic disorders such as obesity and type 1 diabetes mellitus, which have 254 and 244 active products in development, respectively.
T2DM therapeutics can often attract high values in licensing or co-development strategic consolidations. GBI Research's analysis of licensing and co-development deals relating to T2DM therapeutics since 2006 has identified aggregate deal values of $9.2 billion and $9.5 billion, respectively, for deals with disclosed deal values.
Despite this, the majority of first-in-class products in development for T2DM have no disclosed involvement in previous licensing or co-development. Among these products, the range of molecular targets is relatively wide, providing ample and diverse opportunities for potential investors. Entering into a licensing or co-development deal can have significant benefits for both parties, including shared product development risks, financial and R&D resource support, and portfolio or geographical expansion,"" Chisholm concludes
Key Topics Covered:
1 Tables & Figures
2 Executive Summary
2.1 Large and Competitive Market Landscape Driven by Rising Prevalence
2.2 Investment in First-in-Class Innovation Remains Strong
2.3 Opportunities for Investment in First-in-Class Product Development are Considerable
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 GBI Research Report Guidance
4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Classification of Diabetes Mellitus
4.3 Symptoms
4.4 Epidemiology
4.5 Etiology
4.6 Pathophysiology
4.7 Co-morbidities and Complications
4.8 Management and Treatment of Type 2 Diabetes Mellitus
4.8.1 Non-insulin T2DM Therapies
4.9 Insulin-Based T2DM Therapies
4.10 Overview of Marketed Products in Type 2 Diabetes
4.11 Unmet Need and Commercial Opportunities in T2DM
5 Assessment of Pipeline Product Innovation
5.1 Pipeline by Stage of Development, Molecule Type and Molecular Target
5.2 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class
5.3 First-in-Class Programs by Molecular Target Category
6 Type 2 Diabetes Mellitus Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks
6.2 Signaling Pathways and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment
7 First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Insulin Receptor Substrate 1 and Insulin Receptor Substrate
7.2 Pipeline Programs Targeting G-Protein Coupled Receptor Kinase 5 (GRK5)
7.3 Pipeline Programs Targeting Type 2 Angiotensin II Receptor
7.4 Pipeline Programs Targeting Islet Amyloid Polypeptide (IAPP)
7.5 Pipeline Programs Targeting Nacht LRR and PYD Domains Containing Protein
7.6 Pipeline Programs Targeting Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha (PPARGC1A)
7.7 Pipeline Programs Targeting Glucagon
7.8 Pipeline Programs Targeting Alpha Synuclein
7.9 Pipeline Programs Targeting Microtubule Associated Protein Tau
8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals
9 Appendix
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/ql886r/frontier_pharma